Get the Stockscreener App
0.7598
1.31%
0.0098
After Hours:
.75
-0.0098
-1.29%
Neuronetics Inc stock is traded at $0.7598, with a volume of 401.29K.
It is up +1.31% in the last 24 hours and down -13.96% over the past month.
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
See More
Previous Close:
$0.75
Open:
$0.79
24h Volume:
401.29K
Relative Volume:
1.01
Market Cap:
$22.54M
Revenue:
$69.23M
Net Income/Loss:
$-33.10M
P/E Ratio:
-0.6724
EPS:
-1.13
Net Cash Flow:
$-39.26M
1W Performance:
-13.66%
1M Performance:
-13.96%
6M Performance:
-84.04%
1Y Performance:
-43.72%
1-Day Range:
$0.73
$0.8537
1-Week Range:
$0.7241
$0.91
52-Week Range:
$0.664
$5.0699
Neuronetics Inc Stock (STIM) Company Profile
Name
Neuronetics Inc
Sector
Industry
Phone
877-600-7555
Address
3222 PHOENIXVILLE PIKE, MALVERN, PA
Neuronetics Inc Stock (STIM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-21 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-13-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Feb-06-20 | Initiated | BTIG Research | Buy |
| Jul-24-18 | Initiated | Canaccord Genuity | Buy |
Neuronetics Inc Stock (STIM) Latest News
STIM stock rated a Mkt perform by William Blair - Knox Daily
In the Green: Neuronetics Inc (STIM) Closes at 0.75, Up/Down -3.85 from Previous Day - The Dwinnex
Neuronetics' SWOT analysis: merger, cybersecurity woes shape stock outlook - Investing.com India
Neuronetics Expands TMS Access for Adolescents with Depression - MSN
Neuronetics Inc (STIM) deserves closer scrutiny - US Post News
Neuronetics Expands TMS Access for Adolescents with Depression - MyChesCo
Neuronetics Inc [STIM] Shares Fall -6.18 % on Wednesday - Knox Daily
Neuronetics Inc (STIM) Stock: A Year of Declines and Increases - The InvestChronicle
Quarterly Snapshot: Quick and Current Ratios for Neuronetics Inc (STIM) - The Dwinnex
Stoke Therapeutics Inc (STOK) expanding its growth trajectory ahead - SETE News
Neuronetics announces HCSC expanded access to TMS for adolescents - TipRanks
In the Green: NeuroSense Therapeutics Ltd (NRSN) Closes at 1.25, Up/Down -3.50 from Previous Day - The Dwinnex
NeuroMetrix (NASDAQ:NURO) Research Coverage Started at StockNews.com - Defense World
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule - PR Newswire
How did Stoke Therapeutics Inc (STOK) fare last session? - US Post News
Logos Global Management LP Invests $14.19 Million in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Recent Insider Activity Could Benefit Stoke Therapeutics Inc (STOK) - Knox Daily
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 4.7% - MarketBeat
STIM Stock Likely to Gain From Updated TMS Coverage - Zacks Investment Research
STIM Stock Likely to Gain From Updated TMS Coverage - Yahoo Finance
First Eagle Investment Management LLC Purchases 260,000 Shares of Neuronetics, Inc. (NASDAQ:STIM) - Defense World
Neuronetics Expands TMS Coverage, Enhancing Access for MDD Treatment - MyChesCo
Neuronetics Enhances NeuroStar Therapy with New Features - MSN
Expanded Health Policies Enhance TMS Therapy Access for Adolescents and Adults - StockTitan
Neuronetics Enhances NeuroStar Therapy with New Features - MyChesCo
Expanded Health Policies Enhance TMS Therapy Access for Adolescents and Adults - Yahoo Finance
Acadian Asset Management LLC Purchases 62,628 Shares of Neuronetics, Inc. (NASDAQ:STIM) - Defense World
Greenbrook TMS announces acquisition by Neuronetics - Investing.com Canada
Greenbrook TMS announces acquisition by Neuronetics - Investing.com
STIM’s Stock Swings: Riding the 2023 Wave of Ups and Downs - The InvestChronicle
Greenbrook TMS announces acquisition by Neuronetics - Investing.com India
Greenbrook TMS Nears Acquisition by Neuronetics, Shareholders to Vote - TipRanks
Investing in Neuronetics Inc (STIM): What You Must Know - Knox Daily
Financial Health Check: Examining Neuronetics Inc (STIM)’s Key Ratios - The Dwinnex
NeuroStar® Releases Software Upgrades to Elevate Patient Care - Yahoo Finance
Neuronetics Inc (STIM) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
NeuroStar® Releases Software Upgrades to Elevate Patient Care - StockTitan
NRx Pharmaceuticals’ Innovative Treatments for Depression Gain Spotlight - MyChesCo
Neuronetics director Robert Cascella buys $75k of company stock - Investing.com India
Neuronetics director Robert Cascella buys $75k of company stock By Investing.com - Investing.com Australia
Neuronetics director Robert Cascella buys $75k of company stock By Investing.com - Investing.com Canada
Neuronetics director Robert Cascella buys $75k of company stock - Investing.com
Neuronetics director Robert Cascella buys $75k of company stock By Investing.com - Investing.com UK
Transcranial Magnetic Stimulator Market Huge Growth in Future - openPR
Retractable Technologies And 2 Other Penny Stocks Executives Are Buying - Benzinga
Neuronetics' Breakthrough: How NeuroStar Therapy Is Transforming Lives Amid Rising Suicide Rates - MyChesCo
Neuromodulation Market Projected for Strong Growth by 2031 | - openPR
North America Deep Transcranial Magnetic Stimulation Device Market By Applications - அக்னி செய்திகள்
NeuroStar Honors Suicide Prevention Month With Milestone Achievement and Powerful Stories - StockTitan
Butterfly Network And 3 Other Stocks Under $2 Executives Are Aggressively BuyingNeuronetics (NASDAQ:STIM) - Benzinga
Deeper Dive: Understanding Neuronetics Inc (STIM) Through its Various Ratios - The Dwinnex
Neuronetics Inc Stock (STIM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
1.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):